Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03192995 · ClinicalTrials.gov registry record · Phase 2
Treatment With Lorcaserin for Cocaine Use: The TLC Study
A Phase 2 study, sponsored by Glenn-Milo Santos.
- Terminated
- Registry status
- Phase 2
- Development phase
- 22
- Enrollment target
NCT03192995: Clinical Trial Phase 2 study, sponsored by Glenn-Milo Santos.
NCT03192995 is a Phase 2 study that was terminated before completion, run by Glenn-Milo Santos. The registered enrollment target is 22 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (83% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03192995, a Phase 2 study, was terminated before completion, sponsored by Glenn-Milo Santos.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 22 participants
- Enrollment target
Study Summary
This project is a placebo-controlled, double-blind randomized trial evaluating the feasibility, tolerability, acceptability and adherence for lorcaserin among actively using, men who have sex with men (MSM) with cocaine use disorders.The study will enroll 45 individuals who will randomly be assigned to either the treatment (lorcaserin) arm or the placebo arm, to be taken twice a day for 12 weeks.
Primary Outcome
To determine the feasibility of retaining individuals on lorcaserin vs. placebo, the investigators have calculated the mean weekly percentage of follow-up visits of those randomized in the study
Interventions
- DRUG Placebo Oral Tablet
- BEHAVIORAL ACASI
- DRUG lorcaserin
- BEHAVIORAL Substance use counseling
- DIAGNOSTIC_TEST Cocaine metabolites
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2018-01-01 |
| Est. Completion | 2020-06-30 |
| Phase | Phase 2 |
Why NCT03192995 stopped before completion
NCT03192995 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (83% lower).
The record links to 0 conditions, and to 5 interventions - of which Placebo Oral Tablet is the first listed.
NCT03192995 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03192995 about?
NCT03192995 is a clinical study titled "Treatment With Lorcaserin for Cocaine Use: The TLC Study". This project is a placebo-controlled, double-blind randomized trial evaluating the feasibility, tolerability, acceptability and adherence for lorcaserin among actively using, men who have sex with men (MSM) with cocaine use disorders.The study will enroll 45 individuals who will randomly be assigned...
What is the current status of trial NCT03192995?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2018-01-01. Estimated completion is 2020-06-30.
What interventions are being tested in trial NCT03192995?
The interventions under investigation include: Placebo Oral Tablet (DRUG), ACASI (BEHAVIORAL), lorcaserin (DRUG), Substance use counseling (BEHAVIORAL), Cocaine metabolites (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03192995?
This trial is sponsored by Glenn-Milo Santos, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03192995's enrollment target sits among peer trials
22 1790th of 2000 higher than 207 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI